Thursday, 29 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Business Update

Indoco Remedies Business Update

Indoco's CRO AnaCipher received ANVISA Brazil approval for clinical and bioanalytical facilities. This expands its regulatory footprint to conduct bioequivalence studies in Brazil and Latin America.

Source

BSE filing, NSE: INDOCO. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Indoco Remedies Ltd: key numbers

Share price
₹213.75
Market cap
₹1,973 Cr
Revenue (annual)
₹1,845 Cr
Net profit (annual)
₹-95.14 Cr
P/E (TTM)
61.8×Sector 46.1×
Promoter holding
58.92%+0.06% QoQ
FII holding
1.64%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Indoco Remedies Ltd

All →

Other business update announcements

All →